Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences
March 05 2024 - 8:00AM
Business Wire
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical
company focused on the identification, acquisition, development and
commercialization of novel therapies for debilitating rare and
orphan diseases, today announced that it will participate in the
following upcoming investor conferences:
- Leerink Partners Global Biopharma Conference 2024 on Tuesday
March 12, 2024
- Company presentation - Tuesday, March 12 starting at 3:00 p.m.
ET
- Barclays Global Healthcare Conference 2024 on Wednesday March
13, 2024
Visit the Investors and Media section of Mirum’s corporate
website for webcast links and additional information.
About Mirum Pharmaceuticals
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company
dedicated to transforming the treatment of rare diseases affecting
children and adults. Mirum has three approved medications:
LIVMARLI® (maralixibat) oral solution, CHOLBAM® (cholic acid)
capsules, and CHENODAL® (chenodiol) tablets.
LIVMARLI, an IBAT inhibitor, is approved for the treatment of
cholestatic pruritus in patients with Alagille syndrome in the U.S.
(three months and older), in Europe (two months and older), and in
other regions globally. Mirum has also submitted LIVMARLI for
approval in the U.S. in cholestatic pruritus in PFIC patients three
months of age and older and in Europe in PFIC for patients two
months of age and older. CHOLBAM is FDA-approved for the treatment
of bile acid synthesis disorders due to single enzyme deficiencies
and adjunctive treatment of peroxisomal disorders in patients who
show signs or symptoms or liver disease. CHENODAL has received
medical necessity recognition by the FDA to treat patients with
cerebrotendinous xanthomatosis (CTX).
Mirum’s late-stage pipeline includes two investigational
treatments for debilitating liver diseases. Volixibat, an IBAT
inhibitor, is being evaluated in two potentially registrational
studies including the Phase 2b VISTAS study for primary sclerosing
cholangitis and Phase 2b VANTAGE study for primary biliary
cholangitis. Lastly, CHENODAL, has been evaluated in a Phase 3
clinical study, RESTORE, to treat patients with CTX, with positive
topline results reported in 2023.
To learn more about Mirum, visit mirumpharma.com and follow
Mirum on Facebook, LinkedIn, Instagram and Twitter.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240305551076/en/
Investor Contacts: Andrew McKibben investors@mirumpharma.com
Media Contact: Erin Murphy media@mirumpharma.com
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From Apr 2024 to May 2024
Mirum Pharmaceuticals (NASDAQ:MIRM)
Historical Stock Chart
From May 2023 to May 2024